Clinical Trial Translation Services

A single international trial generates translation work in at least a dozen distinct document classes, and treating them identically is how errors and overspend both happen. Each class has its own audience, register and quality requirement.

Core study documents

• Protocol and amendments: the scientific reference document, translated for sites, ethics committees and regulators that require it
• Investigator brochure: dense scientific prose for site staff
• Informed consent forms and participant information sheets: legally significant and readability-critical, covered in detail below
• Case report forms, eCRF screens and completion guidelines: where wording drives data quality
• Patient diaries, apps and reminder materials: lay register, device constraints on text length

Operational and safety documents

• Site contracts and budgets: legal register, handled with our legal translation practice
• Ethics committee correspondence in both directions
• Safety communications: SUSAR notifications, urgent safety measures, dear investigator letters, where turnaround is measured in hours
• Development safety update reports and periodic safety documents
• Lay summaries of results, now an expectation for trials under the EU Clinical Trials Regulation, written in genuinely plain language per locale

We assign each class the right treatment: certified translation with signed statements where a committee requires evidence, standard specialist translation where it does not, and linguistic validation where an instrument measures an endpoint. You are never paying validation rates for a site contract.

Good Clinical Practice requires that consent information is provided in language the participant actually understands, and ethics committees enforce it. A consent form that reads like a contract in the participant's second language fails that test even if every sentence is technically accurate.

How we translate consent materials

Consent forms and participant information sheets are translated by medically qualified linguists into the participant's language at the reading level of the source, then reviewed by a second linguist specifically for comprehension: sentence length, terminology load, and whether an anxious layperson would understand what they are agreeing to. Where a study enrols minors, assent forms are adapted to age-appropriate language rather than mechanically translated.

Evidence for your ethics submission

Committees and IRBs frequently ask for proof that a translation is faithful. We provide, per document and language: a signed translation certificate identifying the translator and their qualifications; back translation by an independent linguist who has not seen the source, where your SOPs or the committee require it; and a reconciliation report explaining any differences the back translation surfaces. This is the documentation package reviewers expect to see, ready to file.

The UK picture

For UK sites, consent materials in community languages are routine for trusts serving diverse populations, and our NHS translation work means the register and format conventions your R&D office expects are already our defaults.

When a questionnaire measures an endpoint, translation stops being a language exercise and becomes a measurement exercise: the translated instrument must measure the same thing as the original, or the data cannot be pooled across countries. That is what linguistic validation is for, and it follows a recognised sequence rather than a single translator's best effort.

The process, step by step

1. Dual forward translation: two independent qualified linguists translate the instrument separately
2. Reconciliation: a third linguist merges the two versions, documenting every decision
3. Back translation: an independent linguist translates the reconciled version back to the source language, blind
4. Review: back translation compared against the original, with developer and clinician input where the instrument owner requires it
5. Cognitive debriefing: the translated instrument is tested with a small group of target-language respondents to confirm items are understood as intended
6. Final report: a full audit trail of versions and decisions, suitable for inclusion in a submission

This mirrors the good-practice principles published by ISPOR and expected by instrument developers and regulators. It is deliberately heavyweight, which is why the honest scoping question matters: administrative documents do not need it, endpoint instruments do. We will tell you which of your documents genuinely warrant validation and which need excellent standard translation, because charging validation rates across a whole study file benefits nobody but the vendor.

eCOA and modality

Where instruments run on screens rather than paper, we handle character limits, string files and screenshots for review, working with your eCOA provider's formats through the same engineering pipeline as our software localisation practice.

Where your trial runs determines who reviews your translations and what they expect to see.

United Kingdom

UK trials go through the combined review route via IRAS, with MHRA and a research ethics committee reviewing together. Participant-facing materials must be suitable for the population being enrolled, which for many UK sites means community-language versions of consent and study materials, with translation certificates in the submission pack.

European Union

The Clinical Trials Regulation moved EU trials onto a single submission through the CTIS portal, but language did not centralise: participant-facing documents in Part II are expected in the language of each member state concerned, and national rules determine exactly which documents must be localised. Lay summaries of results are an obligation under the Regulation. We maintain the per-country picture so your submission team does not have to reconstruct it per trial.

United States and rest of world

FDA expects consent in a language the subject understands, with certified translations the practical standard. Beyond the big three, national requirements vary widely, and this is where a translation partner covering 260+ languages with one project team earns its keep: one glossary, one memory, one accountable point of contact across every country in the study.

The first translation of a study file is the easy part. The hard part is month 30: protocol amendment six, a consent form on version nine, and twelve languages that must all stay in step with each other and with the data already collected.

Version discipline

Every study runs on versioned translation memory: each amendment is translated as a delta against the approved previous version, so unchanged text stays verbatim and reviewers only re-review what actually changed. Terminology is locked in a study glossary at startup, covering drug names, endpoint terms and the phrases your medical monitor cares about, and it is enforced across every linguist who touches the study for its whole life.

Speed when it matters

Routine documents run on standard 48 to 72 hour turnaround. Safety communications do not wait for routine: urgent safety measures, SUSAR-related letters and dear investigator communications go through our same-day service, in parallel across all study languages where needed.

Confidentiality and data protection

Study documents move over encrypted transfer, are stored in the UK, and are handled under NDA. Where source documents contain participant data, we work on pseudonymised text wherever the study design allows, and our processes are GDPR-compliant throughout. Blinding is respected: unblinded safety material is segregated to named linguists who see nothing else on the study.